- Home
Clinical trials - page 2

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
195 result(s)
- ParisMK3475-522 (Keynote-522)A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
MARIE PAULE SABLIN
- ParisDF6215-001A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
EMANUELA ROMANO
- ParisEUonQoLQuality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.
- ParisGSK 219451 - POPSTARPhase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).
AMAURY LERUSTE
- Paris, Saint-CloudREVCCIUse of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia
ABDELMALEK GHIMOUZ
- Breast cancerParis, Saint-CloudHEROESDe-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.
DIANA BELLO ROUFAI
- Paris, Saint-CloudPEACE 7A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).
GILLES CREHANGE, PIERRE GRAFF CAILLEAUD
- Cervical cancerSaint-CloudGYNETA Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
DIANA BELLO ROUFAI
- Lung cancerParisHARMONi-3A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.
PAULINE DU RUSQUEC
- Childhood and adolescent cancersParisHR-NBL2High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
GUDRUN SCHLEIERMACHER
- Saint-CloudIMMUNO-BIL (D48-1 PRODIGE 57)Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
- Thymic tumorsParisIMMUNO-TETCharacterisation of the immune infiltrate and molecular features of Thymic Epithelial Tumours (TETs).
CLEMENCE BASSE
- Childhood and adolescent cancersParisINFORM2 - NIVENT (IC 2018-07)INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies
GUDRUN SCHLEIERMACHER
- Thyroid cancerSaint-CloudINTERMEDIATE-01Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
CAPUCINE RICHARD
- Saint-CloudIONESCO (IFCT-1601)A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer.
MARIE ANGE MASSIANI
- Saint-CloudIROCAS - PRODIGE 52A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting
- ParisLCB-1801-001A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.
EMANUELA ROMANO
- Lung cancerParisLunar- 2LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.
NICOLAS GIRARD
- Saint-CloudM20-621A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).
CLEMENTINE SARKOZY
- Saint-CloudMCLA-128-CL01A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
- Saint-CloudMCLA-128-CL02Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
FRANCOIS-CLEMENT BIDARD
- ParisMCLA-158-CL01Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.
CHRISTOPHE LE TOURNEAU
- ParisMCLA-158-CL02A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma
CHRISTOPHE LE TOURNEAU
- ENT/Head and Neck CancersParisMCLA-158-CL03/LiGeR-HN1A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
CHRISTOPHE LE TOURNEAU
- Thyroid cancerSaint-CloudMIBI-THYRValue of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.
CAPUCINE RICHARD
- Saint-CloudMIRASOLMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.
DIANA BELLO ROUFAI
- Saint-CloudMK 2140-010A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).
CLEMENTINE SARKOZY
- Lung cancerParisMK-2870-004A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.
CATHERINE DANIEL
- Breast cancerParisMK-2870-010An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
DELPHINE LOIRAT